Showing results (31-40 of 66) with videos related to
Sort By:
Pageof 7
Pediatric Blood & Cancer|August 16, 2008
Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology GroupPeter E Zage, Morris Kletzel, Kevin Murray, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2009
Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantationJennifer L McNeer, Morris Kletzel, Alfred Rademaker, et al.Pediatric Transplantation|March 1, 2008
High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapyEvan J Anderson, Judith A Guzman-Cottrill, Morris Kletzel, et al.Journal of Pediatric Hematology/Oncology|November 8, 2016
The Impact of High-resolution HLA-A, HLA-B, HLA-C, and HLA-DRB1 on Transplant-related Outcomes in Single-unit Umbilical Cord Blood Transplantation in Pediatric PatientsAmy E Armstrong, Eileen Smyth, Irene B Helenowski, et al.Hematology/Oncology and Stem Cell Therapy|February 5, 2018
Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host diseaseLarisa Broglie, Alfred Rademaker, John Galvin, et al.Pediatric Blood & Cancer|March 8, 2017
Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplantLarisa Broglie, Irene Helenowski, Lawrence J Jennings, et al.Journal of Clinical Microbiology|November 9, 2007
Identification of adenoviruses in specimens from high-risk pediatric stem cell transplant recipients and controlsXiaotian Zheng, Xiaoyan Lu, Dean D Erdman, et al.British Journal of Haematology|August 5, 2009
High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survivalDavid A Jacobsohn, William T Tse, Stanley Chaleff, et al.Transplantation and Cellular Therapy|May 8, 2026
Excellent long-term survival and immune recovery with reduced-intensity conditioning HCT in inborn errors of immunityHannah Lust, Olatundun Williams, Jennifer Schneiderman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group studyCynthia S Kretschmar, Morris Kletzel, Kevin Murray, et al.Pageof 7